ED50 and Relative Potency of DOTA-Conatumumab and Copper-DOTA-Conatumumab, Compared with Conatumumab, in In Vitro Apoptosis Assay
| ED50 | Percentage coefficient of variation | Relative potency (mean ± SD) | |||
| Sample | ng/mL ± SD | pM ± SD | n | ||
| Conatumumab | 20 ± 4.6 | 135 ± 31 | 23.2 | 100.0% ± 3.4% | 5 |
| DOTA-conatumumab | 19 ± 4.4 | 128 ± 30 | 22.6 | 102.8% ± 11.5% | 5 |
| Copper-DOTA-conatumumab* | 25.0 ± 7.0 | 28.0 | 84.8% ± 2.9% | 3 | |
↵* Molecular weight cannot be accurately determined with mass spectrometry.